BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Dynogen's GI, GU Products To Benefit From $50M Round (BioWorld Today)
News | 04. 20. 2004
Dynogen Pharmaceuticals
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.
